好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Safety and Tolerability of Lacosamide: A Summary of Adverse Events in Epilepsy Clinical Trials
Epilepsy
(-)
081
Authors/Disclosures
Pamela Doty, PhD No disclosure on file
No disclosure on file
Victor Biton, MD (AEP) Dr. Biton has nothing to disclose.
Nathan B. Fountain, MD, FAAN (University of Virginia) Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Fountain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Coda. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Fountain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BrainStorm. Dr. Fountain has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Shackleford. Dr. Fountain has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Acumen. Dr. Fountain has stock in Hexokine.
No disclosure on file
Felix Rosenow, MD No disclosure on file
Antonio Gil-Nagel, MD (Hospital Ruber Internacional) Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $0-$499 for serving as a Consultant for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix . The institution of Dr. Gil-Nagel has received research support from Jazz Pharmaceuticals. The institution of Dr. Gil-Nagel has received research support from PTC Therapeutics. The institution of Dr. Gil-Nagel has received research support from Zogenix. The institution of Dr. Gil-Nagel has received research support from Agencia Estatal Innovacion.
No disclosure on file
No disclosure on file